uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor ...
November 05 2019 - 7:00AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that the U.S. Patent and Trademark Office
has issued U.S. Patent Number 10,465,180. This patent covers
adeno-associated virus vectors comprising a nucleic acid encoding
FIX-Padua, promoter sequences, transcription termination and
control elements. This patent is uniQure’s third U.S patent, along
with the previously issued U.S. Patent Number 9,982,248 and U.S.
Patent Number 9,249,405, in a patent family that uniQure acquired
in 2017 from the inventor, Professor Paolo Simioni, a renowned
hemophilia expert at the University of Padua, Italy.
“uniQure continues to build a significant
intellectual property portfolio, including its FIX-Padua patents,”
said David Cerveny, chief legal officer at uniQure. “These latest
claims broaden the scope of uniQure’s FIX-Padua patent protection
as they relate to any AAV comprising a nucleic acid encoding
FIX-Padua together with promoter sequences, transcription
termination and control elements. We believe this patent
strengthens our intellectual property portfolio and adds further
protection to the use of the FIX-Padua in AAV gene therapy to treat
hemophilia B.”
The Factor IX Padua variant is a Factor IX
protein carrying a leucine at the R338 position, often called the
“FIX-Padua” or “Padua mutant.” Previously-issued claims focus on
the use of AAV gene therapy with FIX-Padua to treat hemophilia B
and other bleeding disorders, as well as compositions of FIX-Padua
nucleic acids and polypeptides (proteins), as well as their
therapeutic uses.
About uniQure uniQure is delivering on the
promise of gene therapy – single treatments with potentially
curative results. We are leveraging our modular and validated
technology platform to rapidly advance a pipeline of proprietary
and partnered gene therapies to treat patients with hemophilia,
Huntington's disease and cardiovascular
diseases. www.uniQure.com
uniQure Forward-Looking
StatementsThis press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements include, but are not limited to, the scope or strength
of protection provided by our patent portfolio and our ability to
have additional patents issue from our current patent applications.
Our actual results could differ materially from those anticipated
in these forward-looking statements for many reasons, including,
without limitation, risks associated with our and our
collaborators’ clinical development activities, collaboration
arrangements, corporate reorganizations and strategic shifts,
regulatory oversight, product commercialization and intellectual
property claims, as well as the risks, uncertainties and other
factors described under the heading "Risk Factors" in uniQure’s
Quarterly Report on Form 10-Q filed on April 30, 2018. Given these
risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
uniQure Contacts:
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: +31 6 52 33 15 79 |
Mobile: 339-223-8541 |
m.cantor@uniQure.com |
e.mulder@uniQure.com |
t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024